SAN DIEGO, CA--(Marketwire - November 03, 2011) - Cytori Therapeutics (NASDAQ: CYTX) today is reporting its third quarter 2011 business update and financial results.
Product revenues for the third quarter of 2011 increased to $2.1 million, compared to $1.5 million in the third quarter of 2010. Gross profit increased to $1.2 million with a gross margin of 56% in the third quarter of 2011, compared to a gross profit of $0.6 million and a gross margin of 39% in the third quarter of 2010.
Net cash used in operating activities improved to $7.9 million in the third quarter of 2011 from $9.0 million in the second quarter of 2011. Third quarter 2011 operating expenses, excluding related to the change in the fair value of the warrant and option liabilities were $10.0 million, compared with $10.9 million in the second quarter of 2011. At the end of the third quarter, Cytori had $40.8 million in cash and cash equivalents and $2.0 million in accounts receivable.
"In the third quarter, we improved our cash position, reduced operating expenses and favorably amended our loan facility led by GE Capital," said Mark E. Saad, chief financial officer. "The equity agreement with Seaside 88 was an important factor in achieving the amended loan terms which significantly extended maturity and deferred principal payments. Expenses improved in Q3 compared to Q2, with reductions sales and marketing costs that reflect more targeted sales efforts."
"This quarter, we made progress building market access for our lead breast reconstruction and cardiovascular therapies," said Christopher J. Calhoun, chief executive officer. "We also continued to generate revenues from a mix of products sold principally into the translational research and cosmetic surgery markets. Operationally, we are focused on ensuring revenue is achieved in a regionally profitable manner and lowering our cash utilization rate. This is reflected in the reduction in net cash used in operating activities during the quarter."
Recent progress to establish European market access for breast reconstruction includes:
- Final 12-month RESTORE 2 trial results presented in September at the Oncoplastic Reconstructive Breast Society meeting in the UK
- Final manuscript completed for the RESTORE 2 trial and under peer-review for publication
- Favorable economic assessment of Celution® from NHS National Innovation Centre (NIC) in the UK
- Inclusion of breast reconstruction therapy in joint British surgical, reconstructive and aesthetic society guidelines
Progress in our cardiovascular pipeline includes:
- Completed US chronic myocardial ischemia pre-IDE meeting with FDA
- US IDE/PMA pilot (Phase I/II) application submission expected Q4 2011
- EU notified body application for 'no option chronic heart disease' indications-for-use submitted, under evaluation
- EU pivotal (Phase II/III) prospective acute myocardial infarction trial (ADVANCE) initiated
- Final manuscript completed for APOLLO trial and under peer-review for publication
Conference Call Information and Shareholder Letter
Cytori will host a management conference call at 5:00 p.m. Eastern Time today to further discuss these results. The live audio webcast of the conference call may be accessed under "Webcasts" in the Investor Relations section of Cytori's website (http://ir.cytoritx.com). The webcast will be available live and by replay two hours after the call and archived for one year. More details on our business are contained in the 'November 2011 Shareholder Letter' which is posted on the homepage of our investor relations website.
About Cytori
Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold in multiple countries for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding our ongoing efforts to build market access for breast reconstruction and cardiovascular therapies, to ensure that revenues are achieved in a regionally profitable manner, and to lower our quarterly cash utilization rate, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, risks related to our history of operating losses, the need for further financing and our ability to access the necessary additional capital for our business, the quality and effectiveness of our products, the effectiveness of our regulatory and sales and marketing programs, the quality and acceptance of our clinical data, dependence on third party performance and the risk of natural disasters and other occurrences that may disrupt the normal business cycles in areas of our global operations, as well as other risks and uncertainties described under the "Risk Factors" section in Cytori's Securities and Exchange Commission Filings on Form 10-K and Form 10-Q. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
CYTORI THERAPEUTICS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
As of As of
September 30, December 31,
2011 2010
------------- -------------
Assets
Current assets:
Cash and cash equivalents $ 40,803,000 $ 52,668,000
Accounts receivable, net of reserves of
$265,000 and $306,000 in 2011 and 2010,
respectively 1,967,000 2,073,000
Inventories, net 4,153,000 3,378,000
Other current assets 702,000 834,000
------------- -------------
Total current assets 47,625,000 58,953,000
Property and equipment, net 1,788,000 1,684,000
Restricted cash and cash equivalents 350,000 350,000
Investment in joint venture 306,000 459,000
Other assets 1,330,000 566,000
Intangibles, net 247,000 413,000
Goodwill 3,922,000 3,922,000
------------- -------------
Total assets $ 55,568,000 $ 66,347,000
============= =============
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable and accrued expenses $ 6,374,000 $ 6,770,000
Current portion of long-term obligations 69,000 6,453,000
------------- -------------
Total current liabilities 6,443,000 13,223,000
Deferred revenues, related party 4,281,000 5,512,000
Deferred revenues 5,118,000 4,929,000
Warrant liability 1,273,000 4,987,000
Option liability 1,850,000 1,170,000
Long-term deferred rent 468,000 398,000
Long-term obligations, net of discount, less
current portion 24,209,000 13,255,000
------------- -------------
Total liabilities 43,642,000 43,474,000
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000
shares authorized; -0- shares issued and
outstanding in 2011 and 2010 -- --
Common stock, $0.001 par value; 95,000,000
shares authorized; 54,834,683 and
51,955,265 shares issued and 54,834,683 and
51,955,265 shares outstanding in 2011 and
2010, respectively 55,000 52,000
Additional paid-in capital 247,413,000 232,819,000
Accumulated deficit (235,542,000) (209,998,000)
------------- -------------
Total stockholders' equity 11,926,000 22,873,000
------------- -------------
Total liabilities and stockholders' equity $ 55,568,000 $ 66,347,000
============= =============
CYTORI THERAPEUTICS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
For the Three Months For the Nine Months
Ended September 30, Ended September 30,
-------------------------- --------------------------
2011 2010 2011 2010
------------ ------------ ------------ ------------
Product revenues:
Related party $ -- $ 581,000 $ -- $ 590,000
Third party 2,134,000 938,000 5,908,000 5,286,000
------------ ------------ ------------ ------------
2,134,000 1,519,000 5,908,000 5,876,000
------------ ------------ ------------ ------------
Cost of product
revenues 942,000 920,000 2,893,000 2,733,000
------------ ------------ ------------ ------------
Gross profit 1,192,000 599,000 3,015,000 3,143,000
------------ ------------ ------------ ------------
Development
revenues:
Development,
related party -- -- 1,231,000 2,122,000
Research grant and
other 5,000 65,000 19,000 93,000
------------ ------------ ------------ ------------
5,000 65,000 1,250,000 2,215,000
------------ ------------ ------------ ------------
Operating expenses:
Research and
development 2,830,000 2,480,000 8,948,000 7,026,000
Sales and
marketing 3,618,000 2,932,000 10,560,000 7,356,000
General and
administrative 3,538,000 3,060,000 11,230,000 9,331,000
Change in fair
value of warrant
liability (1,536,000) 1,803,000 (3,714,000) (1,824,000)
Change in fair
value of option
liability 570,000 (20,000) 680,000 180,000
------------ ------------ ------------ ------------
Total operating
expenses 9,020,000 10,255,000 27,704,000 22,069,000
------------ ------------ ------------ ------------
Operating loss (7,823,000) (9,591,000) (23,439,000) (16,711,000)
------------ ------------ ------------ ------------
Other income
(expense):
Interest income 3,000 3,000 7,000 6,000
Interest expense (489,000) (759,000) (1,923,000) (1,288,000)
Other income
(expense), net 25,000 (27,000) (36,000) (152,000)
Equity loss from
investment in
joint venture (51,000) (43,000) (153,000) (98,000)
------------ ------------ ------------ ------------
Total other
expense (512,000) (826,000) (2,105,000) (1,532,000)
------------ ------------ ------------ ------------
Net loss $ (8,335,000) $(10,417,000) $(25,544,000) $(18,243,000)
============ ============ ============ ============
Basic and diluted
net loss per common
share $ (0.15) $ (0.23) $ (0.48) $ (0.40)
============ ============ ============ ============
Basic and diluted
weighted average
common shares 53,900,250 45,905,580 52,775,861 45,185,774
============ ============ ============ ============
CYTORI THERAPEUTICS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
For the Nine Months Ended
September 30,
----------------------------
2011 2010
------------- -------------
Cash flows from operating activities:
Net loss $ (25,544,000) $ (18,243,000)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 621,000 772,000
Amortization of deferred financing costs
and debt discount 471,000 449,000
Provision for doubtful accounts 274,000 428,000
Change in fair value of warrant liability (3,714,000) (1,824,000)
Change in fair value of option liability 680,000 180,000
Share-based compensation expense 2,578,000 2,294,000
Equity loss from investment in joint
venture 153,000 98,000
Increases (decreases) in cash caused by
changes in operating assets and
liabilities:
Accounts receivable (168,000) (452,000)
Inventories (775,000) (476,000)
Other current assets 132,000 (104,000)
Other assets (764,000) (64,000)
Accounts payable and accrued expenses (396,000) (72,000)
Deferred revenues, related party (1,231,000) (2,122,000)
Deferred revenues 189,000 29,000
Long-term deferred rent 70,000 302,000
------------- -------------
Net cash used in operating activities (27,424,000) (18,805,000)
------------- -------------
Cash flows from investing activities:
Purchases of property and equipment (458,000) (473,000)
Cash invested in restricted cash -- (350,000)
Investment in joint venture -- (330,000)
------------- -------------
Net cash used in investing activities (458,000) (1,153,000)
------------- -------------
Cash flows from financing activities:
Principal payments on long-term debt (4,460,000) (5,454,000)
Proceeds from long-term debt 9,444,000 20,000,000
Debt issuance costs and loan fees (719,000) (559,000)
Proceeds from exercise of employee stock
options and warrants 2,849,000 7,050,000
Proceeds from sale of common stock and
warrants 9,038,000 17,314,000
Costs from sale of common stock and warrants (135,000) (518,000)
------------- -------------
Net cash provided by financing
activities 16,017,000 37,833,000
------------- -------------
Net increase (decrease) in cash and
cash equivalents (11,865,000) 17,875,000
Cash and cash equivalents at beginning of
period 52,668,000 12,854,000
------------- -------------
Cash and cash equivalents at end of period $ 40,803,000 $ 30,729,000
============= =============
